The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2021 | CHRONOS-3: copanlisib plus rituximab for relapsed iNHL
Matthew Matasar, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, shares an update on the randomized Phase III CHRONOS-3 trial (NCT02367040) of copanlisib plus rituximab versus rituximab and placebo in patients with relapsed indolent non-Hodgkin lymphoma (iNHL). At a median follow-up of 19.2 months, copanlisib plus rituximab demonstrated superior efficacy compared to placebo plus rituximab in patients with relapsed iNHL, with a median progression-free survival (PFS) of 21.5 months versus 13.8 months. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
Disclosures
Matthew Matasar, MD, has received support and honoraria from Bayer and Roche.
